Company Overview of Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. researches, develops, manufactures, markets, and sells prescription pharmaceutical products. Its products include Vivelle-Dot and Estradot, which are transdermal estrogen patches; CombiPatch and Estalis, which are combination estrogen/progestogen patches; Stavzor, a delayed release valproic acid softgel; Pexeva, a paroxetine mesylate; Lithobid, a lithium carbonate; Brisdelle, a paroxetine capsule for the treatment of vasomotor symptoms associated with menopause; and estradiol transdermal system for the prevention of postmenopausal osteoporosis. It also manufactures Daytrana, a prescription central nervous system stimulant patch system for the treatment of ADHD in ...
11960 SW 144th Street
Miami, FL 33186
Founded in 1987
Key Executives for Noven Pharmaceuticals, Inc.
Chief Financial Officer, Vice President and Treasurer
Vice President of Operations
Chief Scientific Officer and Vice President
Chief Medical Officer and Executive Vice President of Product Development
Compensation as of Fiscal Year 2015.
Noven Pharmaceuticals, Inc. Key Developments
Noven Pharmaceuticals, Inc. Announces Management Changes
Jan 5 16
Noven Pharmaceuticals, Inc. announced that Jeff Mihm has been appointed as Noven’s Chief Executive Officer, succeeding Jeffrey Eisenberg. Mr. Mihm joined Noven in 2003 and since then has been consistently promoted to senior leadership positions of increasing scope and importance. Most recently, he served as Vice President, Chief Administrative Officer & General Counsel, where he oversaw Noven’s Business Development, Corporate Affairs, Human Resources, Information Technology and Legal/Compliance functions. Prior to Noven, he served as Senior Corporate Counsel to Panamerican Beverages, Inc., and previously was a partner with the law firm of Steel Hector & Davis (now part of Squire Patton Boggs). John Choi has been appointed as Vice President, Chief Financial Officer & Treasurer, succeeding Michael Price. Mr. Choi has served Noven since 2010, most recently as Noven’s Executive Director – Business Planning & Analysis. Prior to Noven, Mr. Choi served as Director of Commercial Operations & Planning for Ther-Rx (a branded pharmaceutical division of KV Pharmaceuticals). Michael Greene has been appointed as Vice President, General Counsel & Corporate Secretary, succeeding Jeff Mihm in those roles. Mr. Greene has served Noven since 2010, most recently as Noven’s Deputy General Counsel & Executive Director – Alliance Management. Prior to Noven, Mr. Greene was an attorney at the law firm of Paul, Hastings, Janofsky & Walker, where he specialized in mergers and acquisitions (M&A) and other complex corporate transactions, including pharmaceutical industry transactions.
Noven Pharmaceuticals, Inc. Presents at BIO-Europe 2015, Nov-02-2015
Oct 9 15
Noven Pharmaceuticals, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Noven Pharmaceuticals, Inc. Replaces Andrew Panagy with Scott Briggs as Vice President, Marketing & Sales
Mar 30 15
Noven Pharmaceuticals, Inc. announced the appointment of Scott Briggs as the company’s new Vice President, Marketing & Sales, succeeding Andrew Panagy, who is retiring. In this role, reporting to Jeffrey Eisenberg, the company’s President and Chief Executive Officer, Briggs is responsible for all marketing and sales activities at Noven and Noven Therapeutics (the company’s specialty pharmaceutical business unit). Prior to this appointment, he served as Vice President Women’s Health Sales for Noven Therapeutics, and as Noven’s Executive Director, Marketing and Managed Markets.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|